Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review.
Patients with MPS IV have a clinical disorder quite different from other MPS conditions. The major treatment issue revolves around the prevention of cervical myelopathy, although the other aspects of this multisystem disease should not be forgotten. Management is inevitably multidisciplinary and the paediatrician should play a lead role in the coordination of services for affected patients. The timing of occipito-cervical fusion and the selection of patients for this procedure remain unclear. A prophylactic approach to surgery is suggested in this review, although it is by no means clear that all patients will invariably develop cervical myelopathy if left untreated. Parents of affected children need considerable support in dealing with the affected child and the children themselves need help to try to come to terms with their severe physical disabilities. The Society for Mucopolysaccharide Diseases (55 Hill Avenue, Amersham, Bucks HP6 5BX, UK) has offered many parents and affected individuals considerable help as well as raising significant sums for research. Finally, it is important to remember the genetic nature of the disease and the possibility of prenatal diagnosis in subsequent pregnancies.
Northover
H
H
Willink Biochemical Genetics Unit, Royal Manchester Children's Hospital, Manchester, UK.
Cowie
R A
RA
Wraith
J E
JE
D006331:Heart Diseases / Q000209:etiology; D006801:Humans; D008168:Lung / Q000503:physiopathology; D009085:Mucopolysaccharidosis IV / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D013122:Spinal Diseases / Q000209:etiology